Physician profile
Jane Daly
NPI 1790722742
$7,185.70
in general payments reported to CMS, 2019-2025
30 companies · $990 in 2025
The $990 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $250 · 2021: $24.28 · 2022: $791 · 2023: $2,077 · 2024: $2,335 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,302 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,301.98 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,665.13 | 2022-2025 | Opdivo, Reblozyl, Krazati |
| Janssen Biotech, INC. | $640.54 | 2022-2025 | Erleada, Akeega, Carvykti |
| Merck Sharp & Dohme LLC | $394.49 | 2022-2024 | Keytruda, Welireg |
| Amgen INC. | $360.14 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $325.01 | 2019-2024 | Tagrisso |
| Pharmaessentia USA Corporation | $265.09 | 2024-2025 | Besremi |
| Glaxosmithkline, LLC. | $259.65 | 2023-2024 | Jemperli, Ojjaara, Zejula |
| Gilead Sciences, INC. | $258.16 | 2022-2025 | Trodelvy |
| Celgene Corporation | $257.81 | 2020-2023 | Pomalyst, Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $250.00 | 2024-2025 | |
| Pfizer INC. | $249.73 | 2023-2025 | |
| Lilly USA, LLC | $239.13 | 2024-2025 | Jaypirca, Verzenio |
| Seagen INC. | $223.88 | 2022-2023 | Tukysa |
| Daiichi Sankyo INC. | $222.98 | 2023-2024 | Enhertu |
| Mirati Therapeutics, INC. | $171.49 | 2023 | Krazati |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $135.00 | 2019 | |
| Novo Nordisk INC | $125.00 | 2019 | |
| Emd Serono, INC. | $125.00 | 2024 | |
| Stemline Therapeutics INC. | $125.00 | 2023 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $125.00 | 2023 | Imbruvica |
| Incyte Corporation | $125.00 | 2025 | Jakafi |
| Exelixis INC. | $125.00 | 2023 | Cabometyx |
| Abbvie INC. | $124.99 | 2023 | Epkinly |
| Taiho Oncology, INC. | $119.20 | 2024 | |
| Adc Therapeutics America, INC. | $116.89 | 2025 | |
| Genentech USA, INC. | $57.52 | 2023 | Polivy, Columvi, Phesgo |
| Sanofi Pasteur INC. | $47.44 | 2019-2021 | |
| Eisai INC. | $34.12 | 2024 | |
| Puma Biotechnology, INC. | $17.31 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.